Robert Taylor, MD
Cardiovascular Disease · Albuquerque, NMNPI 1750397360
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Novartis at 37.3% of the total. Reporting peaked in 2024 at $1,559 and has fallen 52.7% since, to $737 in 2025.
Across 257 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Boehringer Ingelheim$456
- Abiomed$421
- Merck$403
- Boston Scientific$399
- AstraZeneca$374
- plus $1K from 20 others
What the payments were for
- Food & beverage$5,61999%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 114 | $2,107 |
| Boehringer Ingelheim | 20 | $456 |
| Abiomed | 12 | $421 |
| Merck | 25 | $403 |
| Boston Scientific | 5 | $399 |
| AstraZeneca | 15 | $374 |
| Pfizer | 11 | $279 |
| Johnson & Johnson(2 entities) | 8 | $260 |
| E.r. Squibb & Sons, L.L.C. | 8 | $246 |
| Amgen | 7 | $109 |
| Philips North America LLC | 2 | $98 |
| Scpharmaceuticals Inc. | 4 | $87 |
| Cardiva Medical, Inc. | 1 | $54 |
| Actelion Pharmaceuticals US, Inc. | 2 | $53 |
| Abbott | 3 | $46 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $45 |
| Grifols USA, LLC | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Novo Nordisk | 1 | $22 |
| Cvrx, Inc. | 2 | $19 |
| Baxter Healthcare | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
| Inogen, Inc. | 3 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$220
- WATCHMAN Access System$139
- XARELTO$130
- FARXIGA$123
- JARDIANCE$121
- ENTRESTO$117
- CAMZYOS$114
- Impella$113
How this compares
$5,654 in reported general payments places this provider in the 80th percentile of 101 cardiovascular disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,232 | $1,025,777 |
| XareltoRivaroxaban | 379 | $401,574 |
| EntrestoSacubitril/Valsartan | 275 | $271,868 |
| JardianceEmpagliflozin | 151 | $114,906 |
| Repatha SureclickEvolocumab | 110 | $68,120 |
| Metoprolol Succinate | 1,607 | $25,437 |
| FarxigaDapagliflozin Propanediol | 23 | $15,087 |
| Flecainide Acetate | 458 | $13,490 |
| Praluent PenAlirocumab | 27 | $13,441 |
| Atorvastatin Calcium | 953 | $13,164 |
| Repatha SyringeEvolocumab | 16 | $12,549 |
| Carvedilol | 582 | $7,549 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 30 | $7,250 |
| Warfarin Sodium | 626 | $7,232 |
| Losartan Potassium | 615 | $7,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $279 | $1,025,7771,232 claims |
| Johnson & JohnsonXarelto | $260 | $401,574379 claims |
| NovartisEntresto | $2,107 | $271,868275 claims |
| Boehringer IngelheimJardiance | $456 | $114,906151 claims |
| AstraZenecaFarxiga | $374 | $15,08723 claims |
| AmgenCorlanor | $109 | $5,51212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 101 cardiovascular disease providers in New Mexico.
Other cardiovascular disease in Albuquerque
- Abinash AchrekarAlbuquerque$88K
- Adam BanksAlbuquerque$38K
- Stacey CleggAlbuquerque$21K
- Leonardo MaciasAlbuquerque$15K
- Carolina Ponce OrellanaAlbuquerque$12K
- Phillip CampAlbuquerque$11K
- Warren LaskeyAlbuquerque$10K
- Kayvan ElliniAlbuquerque$10K
- Bilal AlqamAlbuquerque$8K
- Daniel FriedmanAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.